Abstracts of the 5th International Meeting of The Onassis Cardiac Surgery Center - September 2010
Brothers JA, McBride MG, Seliem MA, et al. Evaluation of myocardial ischemia after surgical repair of anomalous aortic origin of a coronory artery in a series of pediatric patients. J Am Coll Cardiol. 2007;50:2078-2082.nCheitlin MD. Finding asymptomatic people with a coronary artery arising from the wrong sinus of Valsalva: consequences arising from knowing the anomaly to be familial. J Am Coll Cardiol. 2008;51:2065-2067.nCheitlin MD, De Castro CM, McAllister HA. Sudden death as a complication of anomalous left coronary origin from the anterior sinus of Valsalva, A not-so-minor congenital anomaly. Circulation. 1974;50:780-787.nDavies JE, Burkhart HM, Dearani JA, et al. Surgical management of anomalous aortic origin of a coronary artery. Ann Thor Surg. 2009;88:844-848.nErez E, Tam VK, Doublin NA, Stakes J. Anomalous coronary artery with aortic origin and course between the great arteries: improved diagnosis, anatomic findings, and surgical treatment. Ann Thorac Surg. 2006;82:973-977.nGersony WM Management of anomalous coronary artery from the contralateral sinus. J Am Coll Cardiol. 2007;50:2083-2084.nKaushal S, Backer CL, Walker H, Russell H, Koenig P, Rigsby C, Mavroudis C. Surgical outcomes for anomalous aortic origin of the coronary arteries: emphasizing intramural length with symptoms. Ann Thorac Surg. 2011 (Submitted for presentation to the 2011 Annual STS Meeting).nMaron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064-1075.nMumtaz MA, Lorber RE, Arruda J, Petterson BG, Mavroudis C. Surgery for anomalous aortic origin of the coronary arteries. Ann Thorac Surg. 2010;90.nMustafa I, Gula G, Radley-Smith R, Durrer S, Yacoub M. Anomalous origin of the left coronary artery from the anterior aortic sinus: a potential cause of sudden death. Anatomic characterization and surgical treatment. J Thorac Cardiovasc Surg. 1981;82:297-300.nRomp RL, Herlong JR, Landolfo CK, et al. Outcome of unroofing procedure for repair of anomalous aortic origin of left or right coronary artery. Ann Thorac Surg. 2003;76:589-596.nTaylor AJ, Rogan KM, Virmani R. Sudden cardiac death associated with isolated congenital coronary artery anomalies. J Am Coll Cardiol. 1992;20(3):640-647.nVan Son JA, Mohr FW. Modified unroofing procedure in anomalous aortic origin of left or right coronary artery. Ann Thorac Surg. 1997;64(2):568-569.nGL Bird, HE Jeffries, DJ Licht, et al. Neurological complications associated with treatment of patients with congenital heart disease: consensus definitions from the Multi-Societal Database committee for Pediatric and Congenital Heart Disease. Cardiol Young. 2008;18:234-239.nRL Sherlock, PS McQuillen, SP Miller. Preventing brain injury in newborns with congenital heart disease. Stroke. 2009; 40:327-332nGD Williams, C Ramamoorthy. Brain monitoring and protection during paediatric cardiac surgery. Semin Cardiothorac Vasc Anesth. 2007;11:59-65.nMacedo FIB, Carvalho EM, Gologorsky E, Barron M, Hassan M, Salerno TA: Gas exchange during lung perfusion/ventilation during cardiopulmonary bypass: Preliminary results of a pilot study. Open Journal of Cardiovascular Surgery 2010; 2: 1-7nMacedo FIB, Carvalho EM, Gologorski E, Salerno TA: Lung/ventilation perfusion may reduce pulmonary injury during cardiopulmonary bypass. RE: Imura et al. J. Thorac Cardiovasc Surg 2010; 139: 234-236.nGabriel EA, Locali RF, Almeida LS, Matsuoka PK, Venerando PS, Silva IG, Szarf G, Lederman HM, Souza MM, Parra ER, Capelozzi VL, Salerno TA, Buffolo E: Lung perfusion during cardiac surgery with cardiopulmonary bypass: is it necessary? Interact Cardiovasc Thorac Surg 2008; Sept 10.nAugoustides JG, Wolfe Y, Walsh EK, Szeto WY. Recent advances in aortic valve disease: highlights from a bicuspid aortic valve to transcatheter aortic valve replacement. J Cardiothorac Vasc Anesth. 2009;23:569-76.nBauer F, Eltchaninoff H, Tron C, et al. Acute improvement in global and regional left ventricular systolic function after percutaneous heart valve implantation in patients with symptomatic aortic stenosis. Circulation. 2004;110:1473-6.nBauer F, Lemercier M, Zajarias A, Tron C, Eltchaninoff H, Cribier A. Immediate and long-term echocardiographic findings after transcatheter aortic valve implantation for the treatment of aortic stenosis: the Cribier-Edwards/Edwards-Sapien valve experience. J Am Soc Echocardiogr. 2010;23:370-6.nBillings FT 4th, Kodali Sk, Shanewise JS. Transcatheter aortic valve implantation: anesthetic considerations. Anesth Analg. 2009;108:1453-62.nCovello RD, Maj G, Landoni G, et al. Anesthetic management of percutaneous aortic valve implantation: focus on challenges encountered and proposed solutions. J Cardiothorac Vasc Anesth. 2009;23:280-5.nFassl J, Walther T, Groesdonk HV, et al. Anesthesia management for transapical transcatheter aortic valve implantation: a case series. J Cardiothorac Vasc Anesth. 2009;23:286-91.nFassl J, Augoustides JG. Transcatheter aortic valve implantation—part 1: development and status of the procedure. J Cardiothorac Vasc Anesth. 2010;24:498-505.nFassl J, Augoustides JG. Transcatheter aortic valve implantation—part 2: anesthesia management. J Cardiothorac Vasc Anesth. 2010;24:691-9.nGuinot PG, Depoix JP, Etchegoyen L, et al. Anesthesia and perioperative management of patients undergoing transcatheter aortic valve implantation: analysis of 90 consecutive patients with focus on perioperative complications. J Cardiothorac Vasc Anesth. 2010. In press.nMoss RR, Ivens E, Pasupati S, et al. Role of echocardiography in percutaneous aortic valve implantation. JACC Cardiovasc Imaging. 2008;1:15-24.nCribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006-3008.nThomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic bioprosthesis European outcome (SOURCE) Registry. A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2010;122:62-69.nWalther T, Falk V, Kempfert J, et al. Transapical minimally invasive aortic valve implantation: the initial 50 patients. Eur J Cardiothorac Surg. 2008;33:983-8.nSamolyk KA. State-of-the-art blood management in cardiac surgery. Semin Cardiothorac Vasc Anesth. 2009;13:118-121.nShibata K, Takamoto S, Kotsuka Y, Sato H. Effectiveness of combined blood conservation measures in thoracic aortic operations with deep hypothermic circulatory arrest. Ann Thorac Surg. 2002;73:739-44.nWang G, Bainbridge D, Martin J, Cheng D. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg. 2009;109:320-30.nAvidan MS, Searleman AC, Storandt M, et al. Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or maijor illness. Anesthesiology. 2009;111:964-70.nGrigore AM, Murray CF, Ramakrishna H, Djaiani G. A core review of temperature regimens and neuroprotection during cardiopulmonary bypass: does rewarming rate matter? Anesth Analg. 2009;109:1741-51.nGrocott HP, Homi M, Puskas F. Cognitive dysfunction after cardiac surgery: revisiting etiology. Semin Cardiothorac Vasc Anesth. 2005;9:123-9.nJungwirth B, Eckel B, Blobner M, Kellermann K, Kochs EF, Mackensen GB. Impact of cardiopulmonary bypass on systemin interleukin-6 release, cerebral nuclear factor-kappa B expression, and neurocognitive outcome in rats. Anesth Analg. 2010;110:312-20.nLeung JM, Sands LP. Long-term cognitive decline: is there a link to surgery and anesthesia? Anesthesiology. 2009;111:931-932.nMurkin JM. Applied neuromonitoring and improving CNS outcomes. Semin Cardiothorac Vasc Anesth. 2005;9:139-142.nNussmeier NA, Searles BE. Inflammatory brain injury after cardiopulmonary bypass: is it real? Anesth Analg. 2010;110:288-90.nWährborg P, Booth JE, Clayton T, et al. Neurophysiological outcome after percutaneous coronary intervention or coronary artery bypass grafting: results from the Stent or Surgery (SoS) Trial. Circulation. 2004;110:3411-7.nErgin A, Muntner P, Sherwin R, He J. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am J Med. 2004;117:219-27.nKitamura A, Iso H, Iida M, et al. Trends in the incidence of coronary heart disease and stroke and the prevalence of cardiovascular risk factors among Japanese men from 1963 to 1994. Am J Med. 2002;112:104-9.nLevi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002;88:119-24.nPanagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas I, Stefanadis C; ATTICA Study. Five-year incidence of cardiovascular disease and its predictors in Greece: the ATTICA study. Vasc Med. 2008;13:113-21.nSans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997;18:1231-48.nEdmunds LH Jr. Managing fibrinolysis without aprotinin. Ann Thorac Surg. 2010;89:324-31.nIndian Polycap Study (TIPS), Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373:1341-51.nKuppuswamy V, Choo WK, Gupta S. Polypill in cardiovascular disease: has its time come? Indian Heart J. 2009,61:322-7.nWald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-32.nSadler TW. Respiratory system. In: Sadler TW, ed. Langman's Medical Embryology. 7th ed. Baltimore, Md: Williams & Wilkings; 1995.nCongenital abnormalities. In: Hasleton PS, ed. Spencer's Pathology of the Lung. 5th ed. New York, NY: McGraw-Hill; 1996.nStocker JT, Madewell JE, Drake RM. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Human Pathol. 1977;8:155-71.nStocker JT. Congenital pulmonary airway malformation: a new name for and an expanded classification for congenital cystic adenomatoid malformation of the lung. Histopathology. 2002;41(Suppl 2):424-30.nStocker JT. Congenital and developmental diseases. In: Dail OH, Hammer SP, eds. Pulmonary Pathology. 2nd ed. Heidelberg, Springer-Verlag, 1994:155.nGossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med. 1998;158:643-61.nAdzick NS, Flake AW, Grombleholme TM. Management of congenital lung lesions. Semin Pediatr Surg. 2003;12;10-6.nWinters WD, Effmann EL, Nghiem HV, Nyberg DA. Disappearing fetal lung masses: importance of postnatal imaging studies. Pediatr Radiol. 1997;27:535-9.nPapagiannopoulos K, Hughes S, Nicholson AG, Goldstaw P. Cystic lung lesions in the pediatric and adult population: surgical experience at the Brompton Hospital. Ann Thor Surg. 2002;73:1594-98.nBogers AJ, Hazebroek FW, Molenaar J, Bos E. Surgical treatment of congenital bronchopulmonary disease in children. Eur J Cardiothorac Surg. 1993;7:117-20.nGranata C, Gambini C, Balducci T, et al. Broncioalveolar carcinoma arising in congenital cystic adenomatoid malformation: a case report in a child and review of malignancies originating in congenital cystic adenomatoid malformation. Pediatr Pulmonol. 1998;25:62-6.nRibet ME, Copin MC, Soots JG, Gossellin BH. Bronchioloalveolar carcinoma and congenital cystic adenomatoid malformation. Ann Thor Surg. 1995;60:1126-8.nPapagiannopoulos KA, Sheppard M, Bush AP, Goldstraw P. Pleuropulmonary blastoma: is prophylactic resection of congenital lung cysts effective? Ann Thor Surg. 2001;72:604-5.nMeachery G, De Soyza A, Nicholson A, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax. 2008;63:725-31.nGanesh JS, Rogers CA, Bonser RS; Banner NR; Steering Group of the UK Cardiothoracic Transplant Audit. Outcome of heart-lung and bilateral sequential lung transplantation for cystic fibrosis: a UK national study. Eur Respir J. 2005;25:964-7.nAlexander C. Diaphragm movements and the diagnosis of diaphragmatic paralysis. Clin Radiol. 1966;17:79-83.nArmstrong P, Wilson AG, Dee P, Hansell DM. Imaging of Diseases of the Chest. 2nd ed. St Louis, Mo: CV Mosby; 1995.nAronberg DJ, Peterson RR, Glazer AS, Sagel SS. Superior diaphragmatic lymphnodes: CT assessment. J Comput Assist Tomogr. 1986;10:937-41.nBatirel HF, Utgur-Batramicli O, Giral A, et al. The size of the esophageal hiatus in gastroesophageal pathophysiology: outcome of intraoperative measurements. J Gastrointest Surg. 2010;14:38-44.nBlair E, Hickam JB. The effect of change in body position on lung volume and intrapulmonary gas mixing in normal subjects. J Clin Invest. 1995;34:383-9.nBrega Massone PP, Lequaglie C, Conti B, Ferro F, Magnani B, Cataldo I. A particular case with long-term follow-up with rare malignant hemangiopericytoma of the lung with metachronous diaphragmatic metaplasis. Thorac Cardiovasc Surg. 2002;50:178-80.nBuckley KM, Whitman GJ, Chew FS. Diaphragmatic pheochromocytoma. AJR Am J Roentgenol. 1995;165:260.nCampobasso P, Schieven E, Gifuini G. Diaphragmatic eventration in pediatric age: indications to surgery and results [in Italian]. Minerva Pediatr. 1993;45:475-80.nChen JC, Wilson SE. Diaphragmatic injuries: recognition and management in sixty-two patients. Am Surg. 1991;57:810-5.nDe Leyn P, Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32:1-8.nDionigi G, Dionigi R, Boni L, Rovera F. Transdiaphragmatic approach to the thorax using mini-invasive devices. Surg Laparosc Endosc Percutan Tech. 2006;16:423-6.nDosios T, Papachristos IC, Chrysopoulos H. Magnetic resonance imaging of blunt traumatic rupture of the right hemidiaphragm. Eur J Cardiothorac Surg. 1993;7:553-4.nFalconer AR, Brown RA, Helms P, Gordon I, Baron JA. Pulmonary sequelae in survivors of congenital diaphragmatic hernia. Thorax. 1990;45:126-9.nFinley DJ, Abu-Rustum NR, Chi DS, Flores R. Reconstructive techniques after diaphragm resection. Thorac Surg Clin. 2009;19:531-5.nFischer JC, Jefferson RA, Arkowitz MS, Stolar CJH. Redefining outcomes in right congenital diaphragmatic hernia. J Pediatr Surg. 2008;43:373-9.nGlassman LR, Spencer FC, Bauman FG, Adams FV, Cotvin SB. Successful plication for postoperative diaphragmatic paralysis in an adult. Ann Thorac Surg. 1994;58:1754-5.nGoudet P, Cheynel N, Ferrand L, et al. Lateral approach to laparoscopic repair of left diaphragmatic ruptures. World J Surg. 2001; 25:1150-4.nIshikawa T, Kohno T, Shibayama T, et al. Thoracoscopic thermal ablation therapy hepatocellular carcinoma located beneath the diaphragm. Endoscopy. 2001;33:697-702.nKhong P, Lazzaro A, Mobbs R. Phrenic nerve stimulation: the Australian experience. J Clin Neurosci. 2010;17:205-8.nMoskowitz RM, Young JL, Box GN, Paré LS, Clayman RV. Retroperitoneal transdiaphragmatic robotic-assisted laparoscopic resection on a left thoracolumbar neurofibroma. JSLS. 2009;13:64-8.nNio M. Congenital diaphragmatic hernia [in Japanese]. Kyobu Geka. 2004;57:800-6.nOkaraki T, Hasegawa S, Urushihara N, et al. Toldt's fascia flap: a new technique for repair large diaphragmatic hernias. Pediatr Surg Int. 2005;21:64-7.nPagliarello G, Carter J. Traumatic injury to the diaphragm: timely diagnosis and treatment. J Trauma. 1992;33:194-7.nRosen DJ, Stavropoulos C, Travis WD, Ashton RC, Bhora FY, Connery CP. Transdiaphragmatic amyloidoma. Ann Thorac Surg. 2008;86:310-2.nSamarakkody U, Klaassen M, Nye B. Reconstruction of congenital agenesis of hemidiaphragm by combined reverse latissimus dorsi and serratus anterior muscle flaps. J Pediatr Surg. 2001;36:1637-40.nShatney CH, Sensaki K, Morgan L. The natural history of stab wounds of the diaphragm: implications for a new management scheme for patients with penetrating thoracoabdominal trauma. Am Surg. 2003;69:508-13.nShaul DB, Danielson PD, McComb JG, Keens TG. Thoracoscopic placement of phrenic nerve electrodes for diaphragmatic pacing in children. J Pedriatr Surg. 2002;37:974-8.nStagnitti F, Priore F, Corona F, et al. Traumatic lesions of the diaphragm [in Italian]. G Chir. 2004;25:276-82.nStylianos S, King TC. Occult diaphragm injuries at celiotomy for left chest stab wounds. Am Surg. 1992;58:364-8.nThomas P, Montardier V, Ragui J, Giudicelli R, Fuentes P. Video-assisted repair of a ruptured right hemidiaphragm. Eur J Cardiothorac Surg. 1994;8:157-9.nTsur H, Lieberman Y, Heim M. Diaphragm mobolization for closure of chest wall defects. Ann Plast Surg. 1984;13:234-8.nUrschel JD, Antkowiak JG, Takita H. Neurilemmoma of the diaphragm. J Oncol. 1994;56:209-11.nLatronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res. 2007;101:1225-36.nNabel EG. Cardiovascular disease. N Engl J Med. 2003;349:60-72.nFrazier L, Johnson RL, Sparks E. Genomics and cardiovascular disease. J Nurs Scholarsh. 2005;37:315-21.nWojakowski W, Tendera M. Mobilization of bone marrow-derived progenitor cells in acute coronary syndromes. Folia Histochem Cytobiol. 2005;43:229-32.nNelson TJ, Behfar A, Yamada S, Martinez-Fernandez A, Terzic A. Stem cell platforms for regenerative medicine. Clin Transl Sci. 2009;2:222-7.nTerzic, A, Nelson, TJ. Regenerative medicine advancing health care 2020. J Am Coll Cardiol. 2010;55:2254-7.nConroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.nLiao Y, McGee DL, Cooper RS, Sutkowski MB. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J. 1999;137:837-45.nPanagiotakos DB, Fitzgerald AP, Pitsavos C, Pipilis A, Graham I, Stefanadis C. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J Cardiol. 2007;48:55-63.nPanagiotakos DB, Stavrinos V. Methodological issues in cardiovascular epidemiology: the risk of determining absolute risk through statistical models. Vasc Health Risk Manag. 2006;2:309-15.nRoques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15:816-23.nACC/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation. 2006;114;e84-231.nVahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28:230-68.nHara H, Pedersen WR, Ladich E, et al. Percutaneous balloon aortic valvuloplasty revisited: time for a renaissance? Circulation. 2007;115;e334-8.nIung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:1231-43.nCharlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis. 2006;15:312-21.nPellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005;111: 3290-5.nOtto CM, Mickel MC, Kennedy JW, et al. Three-year outcome after balloon aortic valvuloplasty: insights into prognosis of valvular aortic stenosis. Circulation. 1994;89:642-50.nLieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol. 1995;26:1522-8.nAndersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation of artificial heart valves: description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur Heart J. 1992;13:704-8.nCribier A, Eltchaninoff H, Bash A, et al. Trans-catheter implantation of balloon-expandable prosthetic heart valves: early results in an animal model. Circulation. 2001;104(Suppl II):I-552.nSochman J, Peregrin JH, Pavcnik D, Timmermans H, Rösch J. Percutaneous transcatheter aortic disc valve prosthesis implantation: a feasibility study. Cardiovasc Intervent Radiol. 2000;23:384-8.nLutter G, Kuklinski D, Berg G, et al. Percutaneous aortic valve replacement: an experimental study. J Thorac Cardiovasc Surg. 2002;123:768-76.nBonhoeffer P, Boudjemline Y, Qureshi SA, et al. Percutaneous insertion of the pulmonary valve. J Am Coll Cardiol. 2002;39:1664-9.nWebb JG, Chandavimol M, Thompson CR, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation. 2006;113:842-50.nKriaras I, Michalopoulos A, Geroulanos S. Evolution of antimicrobial prophylaxis in cardiovascular surgery. Eur J Cardiothorac Surg. 2000;18:440-6.nEdwards FH, Engelman RM, Houck P; Shahian DM, Bridges CR; Society of Thoracic Surgeons. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration. Ann Thorac Surg. 2006;81:397-404.nSteinberg JP, Braun BI, Hellinger WC, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg. 2009;250:10-6.nFish DN, Ohlinger MJ. Antimicrobial resistance: factors and outcomes. Crit Care Clin. 2006;22:291-311.nGualis J, Flórez S, Tamayo E, Alvarez FJ, Castrodeza J, Castaño M. Risk factors for mediastinitis and endocarditis after cardiac surgery. Asian Cardiovasc Thorac Ann. 2009;17:612-6.nWheeler AP. Recent developments in the diagnosis and management of severe sepsis. Chest. 2007;132:1967-76.nRose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failrue. N Engl J Med. 2001;345:1435-43nde Jonge N, Kirkels H, Lahpor JR, et al. Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permenent assisting? J Am Coll Cardiol. 2001;37:1794-9.nJaski BE, Lingle RJ, Kim J, et al. Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: Results of the experience with left ventricular assist device with exercise trial. J Heart Lung Transplant. 1999;18:1031-40.nPruijsten RV, de Jonge N, Kirkels JH, et al. Left ventricular assist device: a functional comparison with heart transplantation. Neth Heart J. 2008;16:41-6.nMancini D, Goldsmith R, Levin H, et al. Comparison of exercise performance in patients with chronic severe heart failure versus left ventricular assist devices. Circulation. 1998;98:1178-83.nForay A, Willimas D, Reemtsma K, Oz M, Mancini D. Assessement of submaximal exercise capacity in patients with ventricular assist devices. Circulation. 1996;94(9 Suppl): 11222-6.nCoats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, haemodynamics, ventilation and autonomic function. Circulation. 1992;85:2119-31.nLaoutaris ID, Dritsas A, Adamopoulos S, et al. Benefits of physical training on exercise capacity, inspiratory muscle function, and quality of life in patients with ventricular assist devices late postimplantation. Eur J Cardiovasc Prev Reahabil. 2010. In press.nLespérance F, Frasure-Smith N, Talajic M, Bourassa MG. Fiveyear risk of cardiac mortality in relation to initial severity and oneyear changes in depression symptoms after myocardial infarction. Circulation. 2002;105:1049-53.nRozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99:2192-217.nRozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice. J Am Coll Cardiol. 2005;45:637-51.nWorld Health Organization (WHO). The global strategy on diet, physical activity and health: Cardiovascular Disease. Geneva, 2003.nMensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26:38-48.nMüller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. Available at: http://www.oxfordjournals.org/our_journals/eurheartj/press_releases/freepdf/ehm604.pdf. http://www.oxfordjournals.org/our_journals/eurheartj/press_releases/freepdf/ehm604.pdf'>http://www.oxfordjournals.org/our_journals/eurheartj/press_releases/freepdf/ehm604.pdfnFord ES, Ajani UA, Croft JB, et al. Explaining the decrease in U. S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-98.nRosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-171.nGiannuzzi P, Saner H, Björnstad H, et al. Secondary prevention through cardiac rehabilitation: position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Eur Heart J. 2003;24:1273-8.nAmerican Association of Cardiovascular and Pulmonary Rehabilitation. Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs—4th Edition. Human Kinetics. 2004.nAmerican College of Sports Medicine. Resource Manual for Guidelines for Exercise Testing and Prescription. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006.nAmerican College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006.nPiepoli MF, Corrà U, Benzer W, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010;17:1-17.nAdes PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med. 2001;345:892-902.nBalady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2007;115:2675-82.nCorrà U, Giannuzzi P, Adamopouos S, et al. Executive summary of the position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology (ESC): core components of cardiac rehabilitation in chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2005;12:321-5.nGiannuzzi P, Mezzani A, Saner H, et al. Physical activity for primary and secondary prevention. Position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil. 2003;10:319-27.nGiannuzzi P, Saner H, Björnstad H, et al. Secondary prevention through cardiac rehabilitation: position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Eur Heart J. 2003;24:1273-8.nGiannuzzi P, Temporelli PL, Marchioli R, et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med. 2008;168:2194-204.nPapadakis S, Reid RD, Coyle D, Beaton L, Angus D, Oldridge N. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex. Eur J Cardiovasc Prev Rehabil. 2008;15:347-53.nPiepoli MF, Corrà U, Benzer W, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Preventio and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010;17:1-17.nPiepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328:189-93.nKinsman L, Rotter T, James E, Snow P, Willis J. What is a clinical pathway? Development of a definition to inform the debate. BMC Med. 2010;8:31.nRycroft-Malone J, Fontenla M, Bick D, Seers K. A realistic evaluation: the case of protocol-based care. Implement Sci. 2010;5:38.nRycroft-Malone J, Fontenla M, Seers K, Bick D. Protocol-based care: the standardisation of decision-making? J Clin Nurs. 2009;18:1490-500.nHalvorsen B, Otterdal K, Dahl TB, et al. Atherosclerotic plaque stability—what determines the fate of a plaque? Prog Cardiovasc Dis. 2008;51:183-94.nNissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-65.nNissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-80.nNicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508.nRodriguez-Granillo GA, Agostoni P, Garcia-Garcia HM, et al. Metaanalysis of the studies assessing temporal changes in coronary plaque volume usingintravascular ultrasound. Am J Cardiol. 2007;99:5-10nPennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J. 2004;25:1940-65.nShellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology. 2004;232:635-52.nPamboucas C, Rokas S. Clinical safety of cardiovascular magnetic resonance: cardiovascular devices and contrast agents. Hellenic J Cardiol. 2008;49:352-6.nShellock FG. Magnetic resonance safety update 2002: implants and devices. J Magn Reson Imaging. 2002;16:485-96.nShellock FG. Biomedical implants and devices: assessment of magnetic field interactions with a 3.0-Tesla MR system. J Magn Reson Imaging. 2002;16:721-32.nLevine GN, Gomes AS, Arai AE, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2007;116:2878-91.nShellock FG, Forder JR. Drug eluting coronary stent: in vitro evaluation of magnet resonance safety at 3 Tesla. J Cardiovasc Magn Reson. 2005;7:415-9.nShellock FG. MR safety at 3-Tesla and coronary artery stents. MRIsafety.com. MRI safety, bioeffects and patient management. March 19, 2008. Available at: http://www.mrisafety.com/safety_article.asp?subject=23'>http://www.mrisafety.com/safety_article.asp?subject=23nPorto I, Selvanayagam J, Ashar V, Neubauer S, Banning AP. Safety of magnetic resonance imaging one to three days after bare metal and drug-eluting stent implantation. Am J Cardiol. 2005;96:366-8.nSyed MA, Carlson K, Murphy M, Ingkanisorn WP, Rhoads KL, Arai AE. Long-term safety of cardiac magnetic resonance imaging performed in the first few days after bare-metal stent implantation. J Magn Reson Imaging. 2006;24:1056-61.nPatel MR, Albert TS, Kandzari DE, et al. Acute myocardial infarction: safety of cardiac MR imaging after percutaneous revascularization with stents. Radiology. 2006;240:674-80.nNijveldt R, Hirsch A, Hofman MB, et al. 3.0 T cardiovascular magnetic resonance in patients treated with coronary stenting for myocardial infarction: evaluation of short term safety and image quality. Int J Cardiovasc Imaging. 2008;24:283-91.nShinbane JS, Colletti PM, Shellock FG. MR in patients with pacemakers and ICDs: defining the issues. J Cardiovasc Magn Reson. 2007;9:5-13.nRoguin A, Zviman MM, Meininger GR, et al. Modern pacemaker and implantable cardioverter/defibrillator systems can be magnetic resonance imaging safe: In vitro and in vivo assessment of safety and function at 1.5 T. Circulation. 2004;110:475-82.nMartin ET, Coman JA, Shellock FG, Pulling CC, Fair R, Jenkins K. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla. J Am Coll Cardiol. 2004;43:1315-24.nShellock FG, Fieno DS, Thomson LJ, Talavage TM, Berman DS. Cardiac pacemaker: in vitro assessment at 1.5 T. Am Heart J. 2006;151:436-43.nNazarian S, Roguin A, Zviman MM, et al. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. Circulation. 2006;114:1277-84.nSommer T, Naehle CP, Yang A, et al. Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non-pacemakerdependent patients: a prospective study with 115 examinations. Circulation. 2006;114:1285-92.nShellock FG, Fischer L, Fieno DS. Cardiac pacemakers and implantable cardioverter defibrillators: in vitro magnetic resonance imaging evaluation at 1.5-tesla. J Cardiovasc Magn Reson. 2007;9:21-31.nHeatlie G, Pennell DJ. Cardiovascular magnetic resonance at 0.5T in five patients with permanent pacemakers. J Cardiovasc Magn Reson. 2007;9:15-9.nFaris OP, Shein M. Food and Drug Administration perspective: magnetic resonance imaging of pacemaker and implantable cardioverter-defibrillator patients. Circulation. 2006;114:1232-3.nConstantine G, Shan K, Flamm SD, Sivananthan MU. Role of MRI in clinical cardiology. Lancet. 2004;363:2162-71.nPerazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol. 2007;2:200-2.nKuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647-9.nPamboucas C, Schmitz S, Nihoyannopoulos P. Magnetic resonance imaging in the detection of myocardial viability: the role of delayed contrast hyperenhancement. Hellenic J Cardiol. 2005;46:108-16.nAnderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9.nKirk P, Roughton M, Porter JP, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-8.nMavrogeni SI, Markussis V, Kaklamanis L, et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol. 2005;75:241-7.nPennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-44.nWood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535-43.nKim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318-26.nKim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-53.nJudd RM, Lugo-Olivieri CH, Arai M, et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation. 1995;92:1902-10.nKim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002.nFieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol. 2000;36:1985-91.nWu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet. 2001;357:21-8.nKaandorp TA, Lamb HJ, Poldermans D, et al. Assessment of right ventricular infarction with contrast-enhanced magnetic resonance imaging. Coron Artery Dis. 2007;18:39-43.nKumar A, Abdel-Aty H, Kriedemann I, et al. Contrast-enhanced cardiovascular magnetic resonance imaging of right ventricular infarction. J Am Coll Cardiol. 2006;48:1969-76.nLarose E, Ganz P, Reynolds HG, et al. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. J Am Coll Cardiol. 2007;49:855-62.nKlein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation. 2002;105:162-7.nWagner A, Mahrholdt H, Holly TA, et al. Contrastenhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374-9.nBondarenko O, Beek AM, Nijveldt R, et al. Functional outcome after revascularization in patients with chronic ischemic heart disease: a quantitative late gadolinium enhancement CMR study evaluating transmural scar extent, wall thickness and periprocedural necrosis. J Cardiovasc Magn Reson. 2007;9:815-21.nMavrogeni S, Manoussakis MN, Karagiorga TC, et al. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum. 2009;61:1121-9.nMavrogeni S, Spargias K, Markussis V, et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm Allergy Drug Targets. 2009;8:390-7.nKaramitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407-24.nNagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation. 1999;99:763-70.nJahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 2007;115:1769-76.nKaramitsos TD, Arnold JR, Pegg TJ, et al. Tolerance and safety of adenosine stress perfusion cardiovascular magnetic resonance imaging in patients with severe coronary artery disease. Int J Cardiovasc Imaging. 2009;25:277-83.nGebker R, Schwitter J, Fleck E, Nagel E. How we perform myocardial perfusion with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2007;9:539-47.nSchwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multiCenter, multivendor, randomized trial. Eur Heart J. 2008;29:480-9.nKwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008;118:1011-20.nFang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25:543-67.nBax JJ, Inzucchi SE, Bonow RO, et al. Cardiac imaging for risk stratification in diabetes. Diabetes Care. 2007;30:1295-304.nMaya L, Villarreal FJ. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. J Mol Cell Cardiol. 2010;48:524-9.nEscaned J, Colmenárez H, Ferrer MC, et al. Diastolic dysfunction in diabetic patients assessed with Doppler echocardiography: relationship with coronary atherosclerotic burden and microcirculatory impairment. Rev Esp Cardiol. 2009;62:1395-403.nFang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol. 2003;41:611-7.nvon Bibra H, Hansen A, Dounis V, Bystedt T, Malmberg K, Rydén L. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart. 2004;90:1483-4.nElhendy A, Tsutsui J, O'Leary EL, Xie F, McGrain AC, Porter TR. Noninvasive dagnosis of coronary artery disease in patients with diabetes by dobutamine stress real-time myocardial contrast perfusion imaging. Diabetes Care. 2005;28:1662-7.nNg AC, Delgado V, Bertini M, et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol. 2009;104:1398-401.nHaffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.nBax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ; ADA. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007;30:2729-36.nRajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol. 2005;45:43-9.nVanzetto G, Halimi S, Hammond T, et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients: prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care. 1999;22:19-26.nDeLorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-proton emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol. 2002;90:827-32.nZellweger MJ, Hachammovitch R, Kang X, et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Eur Heart J. 2004;25:543-50.nGiri S, Shaw LJ, Murthy DR, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation. 2002;105:32-40.nYoung LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: a randomized controlled trial. JAMA. 2009;301:1547-55.nWiersma JJ, Verberne HJ, ten Holt WL, et al. Prognostic value of myocardial perfusion scintigraphy in type 2 diabetic patients with mild, stable angina pectoris. J Nucl Cardiol. 2009;16:524-32.nEeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52:65-73.nBarr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009;52:415-24.nThorn LM, Forsblom C, Wadén J, et al. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2009;32:950-2.nIbanez B, Navarro F, Cordoba M, M-Alberca P, Farre J. Takotsubo transient left ventricular apical ballooning: is intravascular ultrasound the key to resolve the enigma? Heart. 2005;91:102-4.nMintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37:1478-92.nKawaguchi R, Sabate M, Angiolillo DJ, et al. Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal stent and three different formulations of drug-eluting stents in patients with diabetes mellitus. Int J Cardiovasc Imaging. 2008;24:125-32.nLee DY, Eigler N, Fishbein MC, Bhambi B, Maurer G, Siegel RJ. Identification of intracoronary thrombus and demonstration of thrombectomy by intravascular ultrasound imaging. Am J Cardiol. 1994;73:522-3.nNishioka T, Luo H, Berglund H, et al. Absence of focal compensatory enlargement or constriction in diseased human coronary saphenous vein bypass grafts. An intravascular ultrasound study. Circulation. 1996;93:683-90.nNissen SE. Who is at risk for atherosclerotic disease? Lessons from intravascular ultrasound. Am J Med. 2002;112(Suppl 8A):27-33.nIakovou I, Mintz GS, Dangas G, et al. Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. 2003;42:1900-5.nIakovou I, Dangas G, Mintz GS, et al. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. Am J Cardiol. 2004;93:963-8.nIakovou I, Mintz GS, Dangas G, et al. Optimal final lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries. Am J Cardiol. 2003;92:1171-6.nRawn JD. Blood transfusion in cardiac surgery: a silent epidemic revisited. Circulation. 2007;116:2523-4.nEngoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002;74:1180-6.nSpeiss BD. Transfusion and outcome in heart surgery. Ann Thorac Surg. 2002;74:986-7.nFuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-54.nStanescu C. Exercise echocardiography in coronary artery disease. Rom J Intern Med. 2004;42:473-89.nJaafari A, Boukhriss B, Mkadem A, Benyoussef S. Indications for dobutamine stress echocardiography [in French]. Tunis Med. 2003;81:914-8.nKrahwinkel W, Ketteler T, Gödke J, et al. Dobutamine stress echocardiography. Eur Heart J. 1997;18(Suppl D): D9-15.nMcNeill AJ, Fioretti PM, el-Said SM, Salustri A, Forster T, Roelandt JR. Enchanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. Am J Cardiol. 1992;70:41-6.nFletcher GF, Balady GJ, Froelicher VF, Hartley LH, Haskell WL, Pollock ML. Exercise standarts: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 1995;91:580-615.nChen W, Woods SL, Wilkie DJ, Puntillo KA. Gender differences in symptom experiences of patients with acute coronary syndromes. J Pain Symptom Manage. 2005;30:553-62.nLøvlien M, Schei B, Gjengedal E. Are there gender differences related to symptoms of acute myocardial infarction? A Norwegian perspective. Prog Cardiovasc Nurs. 2006;21:14-9.nGoff DC Jr, Mitchell P, Finnegan J, et al. Knowledge of heart attack symptoms in 20 US communities. Results from the Rapid Early Action for Coronary Treatment Community Trial. Prev Med. 2004;38:85-93.nDracup K, McKinley S, Doering LV, et al. Acute coronary syndrome: what do patients know? Arch Intern Med. 2008;168:1049-54.nFeldman C, Kassel M, Cantrell J, et al. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. Eur Respir J. 1999;13:546-51.nNiederman MS. The pathogenesis of airway colonization: lessons learned from the study of bacterial adherence. Eur Respir J. 1994;17:1737-40.nChastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867-903.nMcLaughlin V, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-31.nRimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation. 2001;103;544-8.nWinberg P, Lundell BP, Gustafsson LE. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J. 1994;71:282-6.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).